| Insiders | Shares | % | Avg Price | Total $ | |
|---|---|---|---|---|---|
| Buys | 1 | +1.53M | 82.4% | $38.00 | +$58M |
| Sells | 10 | -327K | 17.6% | $32.44 | -$10.6M |
| Net | -9 | +1.2M | 64.7% | +$47.4M |
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Report Date |
|---|---|---|---|---|---|
| Roivant Sciences Ltd. | Director, 10%+ Owner | $3.03B | +$58M | +1.95% | Oct 2, 2023 |
| Peter Salzmann | Chief Executive Officer, Director | $32.6M | -$3.84M | -10.5% | Aug 21, 2024 |
| Frank Torti | Director | $23M | Apr 2, 2024 | ||
| Julia G. Butchko | Chief Development Officer | $14.3M | -$945K | -6.22% | Aug 21, 2024 |
| William L. Macias | Chief Medical Officer | $11.9M | -$748K | -5.91% | Aug 21, 2024 |
| Eva Renee Barnett | Chief Financial Officer | $11.1M | -$1.49M | -11.8% | Aug 21, 2024 |
| Mark S. Levine | Chief Legal Officer | $10.7M | -$1.23M | -10.3% | Aug 21, 2024 |
| Douglas J. Hughes | Director | $4.52M | Apr 2, 2024 | ||
| George V. Migausky | Director | $4.38M | -$505K | -10.3% | Apr 2, 2024 |
| Atul Pande | Director | $4.14M | -$491K | -10.6% | Apr 2, 2024 |
| Jay S. Stout | Chief Technology Officer | $4.02M | -$287K | -6.67% | Jul 24, 2024 |
| Michael Geffner | Chief Medical Officer | $3.84M | -$573K | -13% | Jul 24, 2024 |
| Andrew J. Fromkin | Director | $3.61M | -$491K | -12% | Apr 2, 2024 |
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|